Wisp Begins Offering Diagnostics Through Partnership with TBD Health - MedCity News - Latest Global News

Wisp Begins Offering Diagnostics Through Partnership with TBD Health – MedCity News

Sexual health company Wisp has expanded its partnership with TBD Health, the company told MedCity News. On Wednesday, the company began offering access to TBD Health’s sexually transmitted infection/disease (STI/STD) testing kits on its website.

San Francisco-based Wisp is a virtual healthcare provider for vaginal health, reproductive health and sexual health. Its direct-to-consumer platform offers contraception as well as treatments for urinary tract infections, genital herpes, bacterial vaginosis and yeast infections. Based in New York City, TBD Health is an online and in-person sexual health care platform. It offers at-home STD testing and emergency contraception, as well as telemedicine consultations. The in-person clinics are located in Las Vegas and Denver.

In January, the companies announced that Wisp telemedicine patients could be referred to TBD Health’s in-person clinics to receive STD testing, PrEP prescriptions, urinary tract infection treatments and other services. Through the expanded partnership, Wisp members can now order TBD Health’s STI/STD testing kits on Wisp’s website for free delivery. You complete the test by providing a urine sample and returning the kit to one of TBD Health’s partner laboratories. If the test is positive, they will consult a TBD doctor to receive treatment and understand next steps.

“We remain committed to providing patients the treatments and care they need, when they need it, without hassle, judgment and without the need for insurance. …This partnership helps us further democratize access to sexual health care and marks the first time we are experimenting with home diagnostics on our platform,” Wisp CEO Monica Cepak said in an email.

Wisp pays TBD Health for its inventory, Cepak added.

The company’s announcement comes at a time when the number of STI cases is increasing. According to the Centers for Disease Control and Prevention, more than 2.5 million cases of syphilis, gonorrhea and chlamydia were reported in the United States in 2022. Between 2018 and 2022, syphilis cases in the United States increased by 80%.

“We recognize that the need for STI/STD treatments and testing options has never been greater,” said Cepak. “Through this partnership, we are meeting patient demand while working to educate consumers about what symptoms look like and what options there are for prevention and post-diagnosis.”

The company also recently added two new medications to its website: M. Hominis Treatment and Ureaplasma Treatment. These bacteria do not usually cause problems, but when imbalanced they can cause pain, discharge, vaginal odor and fertility problems. The drugs are designed to “effectively combat the imbalance of various bacteria and quickly relieve unpleasant genital symptoms,” Cepak said.

Other companies offering sexual health support to consumers include Ro and Hims and Hers.

Sharing Is Caring:

Leave a Comment